EP2964673A4 - Anticorps dirigés contre hgf et compositions les contenant - Google Patents

Anticorps dirigés contre hgf et compositions les contenant Download PDF

Info

Publication number
EP2964673A4
EP2964673A4 EP14767985.6A EP14767985A EP2964673A4 EP 2964673 A4 EP2964673 A4 EP 2964673A4 EP 14767985 A EP14767985 A EP 14767985A EP 2964673 A4 EP2964673 A4 EP 2964673A4
Authority
EP
European Patent Office
Prior art keywords
hgf
antibodies
compositions containing
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14767985.6A
Other languages
German (de)
English (en)
Other versions
EP2964673A2 (fr
Inventor
Benjamin H. Dutzar
Katie ANDERSON
Brian R. Kovacevich
Andrew L. Feldhaus
John A. Latham
Leon F. GARCIA-MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Seattle Biopharmaceuticals Inc
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of EP2964673A2 publication Critical patent/EP2964673A2/fr
Publication of EP2964673A4 publication Critical patent/EP2964673A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14767985.6A 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant Withdrawn EP2964673A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782868P 2013-03-14 2013-03-14
US201361781643P 2013-03-14 2013-03-14
PCT/US2014/029163 WO2014153117A2 (fr) 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant

Publications (2)

Publication Number Publication Date
EP2964673A2 EP2964673A2 (fr) 2016-01-13
EP2964673A4 true EP2964673A4 (fr) 2017-02-22

Family

ID=51581767

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14767985.6A Withdrawn EP2964673A4 (fr) 2013-03-14 2014-03-14 Anticorps dirigés contre hgf et compositions les contenant

Country Status (7)

Country Link
EP (1) EP2964673A4 (fr)
JP (1) JP2016516052A (fr)
KR (1) KR20150140685A (fr)
CN (1) CN105246915A (fr)
CA (1) CA2904743A1 (fr)
TW (2) TW201444868A (fr)
WO (2) WO2014153117A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
EP4054585A1 (fr) 2019-11-05 2022-09-14 Abbvie Inc. Schémas posologiques destinés à être utilisés dans le traitement de la myélofibrose et de troubles liés à mpn par le navitoclax
WO2022228514A1 (fr) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anticorps anti-facteur inhibiteur de la leucémie humaine et son utilisation
WO2024129564A1 (fr) * 2022-12-13 2024-06-20 The Children's Medical Center Corporation Méthodes et compositions pour le traitement d'anomalies vasculaires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (fr) * 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
WO2005107800A1 (fr) * 2004-04-15 2005-11-17 Galaxy Biotech, Llc Anticorps monoclonaux du facteur de croissance des hepatocytes
WO2007143090A2 (fr) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2007143098A2 (fr) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2021463B1 (fr) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Procédé de culture permettant d'obtenir une population clonée de lymphocytes b spécifiques d'antigène
CN101460521A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9539324B2 (en) * 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (fr) * 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
WO2005107800A1 (fr) * 2004-04-15 2005-11-17 Galaxy Biotech, Llc Anticorps monoclonaux du facteur de croissance des hepatocytes
WO2007143090A2 (fr) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2007143098A2 (fr) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. Y. WEN ET AL: "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma", NEURO-ONCOLOGY, vol. 13, no. 4, 1 April 2011 (2011-04-01), pages 437 - 446, XP055084095, ISSN: 1522-8517, DOI: 10.1093/neuonc/noq198 *
T. L. BURGESS ET AL: "Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 2, 1 February 2010 (2010-02-01), US, pages 400 - 409, XP055308025, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0824 *

Also Published As

Publication number Publication date
TW201444868A (zh) 2014-12-01
TW201438737A (zh) 2014-10-16
CN105246915A (zh) 2016-01-13
KR20150140685A (ko) 2015-12-16
JP2016516052A (ja) 2016-06-02
WO2014153166A3 (fr) 2014-12-04
EP2964673A2 (fr) 2016-01-13
CA2904743A1 (fr) 2014-09-25
WO2014153117A2 (fr) 2014-09-25
WO2014153117A3 (fr) 2015-01-08
WO2014153117A9 (fr) 2014-11-27
WO2014153166A2 (fr) 2014-09-25

Similar Documents

Publication Publication Date Title
HK1224218A1 (zh) 穩定的抗體組合物
IL244850A0 (en) Stabilized epinaconazole preparations, and their uses
EP2992097A4 (fr) Compositions et procédés
EP2951283A4 (fr) Compositions et procédés
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP2961382A4 (fr) Compositions topiques et leurs procédés d'utilisation
EP3030266A4 (fr) Compositions topiques et procédés d'utilisation de celles-ci
EP3020778A4 (fr) Composition adhésive
EP2970569A4 (fr) Carbènes persistants et compositions associées
GB201321693D0 (en) Composition and uses thereof
EP2992334A4 (fr) Nouveaux phosphatidylalcanols et leurs compositions
EP2997166A4 (fr) Procédés et compositions d'enrichissement d'analyte
EP2964673A4 (fr) Anticorps dirigés contre hgf et compositions les contenant
EP3064513A4 (fr) Composition contenant un polyrotaxane
EP3062769A4 (fr) Composition sous la forme d'une émulsion
GB201317105D0 (en) Novel Composition
EP3080080A4 (fr) Nouvelles compositions
EP3003299B8 (fr) Nouveaux immunorésolvants n-3: structures et actions
EP3009497A4 (fr) Composition nettoyante
EP2964610A4 (fr) Composition de marquage au 18f à base de vinylsulfone et procédés et utilisations associés
EP3033392A4 (fr) Composition mécano-réactive
EP3081210A4 (fr) Composition cosmétique
EP3074049A4 (fr) Nouvelles compositions capables de pénétrer dans les cellules et leurs procédés d'utilisation
GB201319923D0 (en) Novel composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151009

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101AFI20161014BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170125

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101AFI20170119BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180611

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181023